PROCEPT BioRobotics (PRCT) Liabilities and Shareholders Equity (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $487.1 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 6.22% year-over-year to $487.1 million in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 12.09% increase from a year earlier, with the FY2025 full-year figure at $508.1 million, down 4.86% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $487.1 million, down from $508.1 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for PRCT reached as high as $534.0 million in Q4 2024 and fell as low as $272.4 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $403.1 million across 5 years, with a median of $382.9 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity decreased 12.38% in 2023 and jumped 37.4% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $309.3 million in 2022, then soared by 30.84% to $404.7 million in 2023, then soared by 31.95% to $534.0 million in 2024, then slipped by 4.86% to $508.1 million in 2025, then slipped by 4.14% to $487.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $487.1 million in Q1 2026, $508.1 million in Q4 2025, and $511.5 million in Q3 2025.